Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

by Y. Wang, S. Thongsawat, E. J. Gane, Y. F. Liaw, J. Jia, J. Hou, H. L Y Chan, G. Papatheodoridis, M. Wan, J. Niu, W. Bao, A. Trylesinski, N. V. Naoumov
Published 2018

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

by Y. Wang, S. Thongsawat, E. J. Gane, Y. F. Liaw, J. Jia, J. Hou, H. L Y Chan, G. Papatheodoridis, M. Wan, J. Niu, W. Bao, A. Trylesinski, N. V. Naoumov
Published 2018

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

by Y. F. Liaw, J. D. Jia, H. L.Y. Chan, K. H. Han, T. Tanwandee, W. L. Chuang, D. M. Tan, X. Y. Chen, E. Gane, T. Piratvisuth, L. Chen, Q. Xie, J. J.Y. Sung, C. Wat, C. Bernaards, Y. Cui, P. Marcellin
Published 2018